| Endpoint |
Method Name |
Test Type1 |
Endorsement of Scientific Validity |
Regulatory Acceptance |
| |
|
|
Lead Authority |
Subsequent Endorsement(s) |
International (click here for approved OECD TGs, here for Draft TGs, and here for GDs) |
National/ Regional (for methods not yet accepted internationally) |
| Acute aquatic toxicity |
Upper threshold concentration step-down approach |
In vivo
|
ESAC 17 (2006)
|
|
OECD GD 126 (2010)
|
|
| Acute mammalian toxicity (oral) |
Acute toxic class method |
In vivo
|
|
ESAC 33 (2007)
|
OECD TG 423 (2001)
|
|
| |
Fixed dose procedure |
In vivo
|
|
ESAC 32 (2007)
|
OECD TG 420 (2001)
|
|
| |
Up-and-down procedure |
In vivo
|
ICCVAM (2001)
|
ESAC 34 (2007)
|
OECD TG 425 (2006)
|
|
| |
Normal human keratinocyte neutral red uptake (NHK NRU) assay |
In vitro2
|
ICCVAM (2006)
|
|
OECD GD 129 (2010)
|
US agencies (2008)
|
| |
Balb/c 3T3 neutral red uptake assay |
In vitro2
|
ICCVAM (2006)
|
|
OECD GD 129 (2010)
|
US agencies (2008)
|
| Acute mammalian toxicity (inhalation) |
Acute toxic class method |
In vivo
|
|
|
OECD TG 436 (2009)
|
|
| |
Fixed concentration procedure |
In vivo
|
|
|
Draft TG OECD 433
|
|
| Biologics & Vaccines |
ELISA for erysipelas vaccines batch potency testing |
In vitro
|
ESAC 14 (2002)
|
|
|
European Pharmacopeia
|
| |
ELISA for human tetanus vaccines batch potency testing |
In vitro
|
ESAC 9 (2000)
|
|
|
European Pharmacopeia
|
| |
Toxin binding inhibition test for human tetanus vaccines batch potency testing |
In vitro
|
ESAC 10 (2000)
|
|
|
European Pharmacopeia
|
| Chronic toxicity |
Ending 1-year dog studies of pesticides |
In vivo
|
ESAC 26 (2006)
|
|
|
Revised US EPA Pesticide Data Requirements
|
| Dermal penetration |
In vitro skin absorption methods |
In vitro
|
OECD Expert Group (2002)
|
|
OECD TG 428 (2004)
OECD GD 28 (2004)
Draft OECD Guidance Notes (2010)
|
|
| Endocrine active substances3 |
Androgen receptor binding assay (rat prostate cytosol) |
Ex vivo
|
|
|
|
OPPTS TG 890.1150 (EPA, 2009)
|
| |
Aromatase inhibition assay (human recombinant) |
In vitro
|
|
|
|
OPPTS TG 890.1200 (EPA, 2009)
|
| |
Estrogen receptor (ER)-alpha transcriptional activation assay for estrogen agonists (STTA) |
In vitro
|
OECD/EPA
|
|
OECD TG 455 (2009)
|
OPPTS TG 890.1300
|
| |
Estrogen receptor binding assay rat uterine cytosol (ER-RUC) |
Ex vivo
|
|
|
|
OPPTS TG 890.1250 (EPA, 2009)
|
| |
H295R steroidogenesis assay |
In vitro
|
OECD/EPA
|
|
OECD TG 456 (2011)
|
OPPTS TG 890.1550 (EPA, 2009)
|
| |
US EPA Tier 1 Screening Battery |
In vitro/In vivo
|
|
|
|
US EPA (2009)
|
| |
BG1Luc ER TA test method for estrogen agonists and antagonists |
In vitro
|
ICCVAM (expected 2011)
|
|
|
|
| Eye corrosion |
Bovine corneal opacity permeability (BCOP) test |
In vitro
|
ICCVAM (2007)
|
ESAC 27 (2007)
INVITTOX Protocol 127
JaCVAM (2009)
JaCVAM Regulatory Acceptance Board (2009)
|
OECD TG 437 (2009)
OECD Proficiency Standards
Draft OECD GD on Supplement to TG 437 and 438 (histopathology) (2009)
|
|
| |
Cytosensor Microphysiometer modified (cytotoxicity/cell-based assay) |
In vitro
|
ESAC 40 (2009)4
INVITTOX Protocol 102 modified
|
ICCVAM (2010)5
|
Draft OECD TG (2010)
|
|
| |
Fluorescein Leakage (cytotoxicity/cell-based assay) |
In vitro
|
ESAC 40 (2009)6
INVITTOX Protocol 71
|
|
Draft OECD TG (2010)
|
|
| |
Hen's egg test-chorioallantoic membrane (HET-CAM) |
In vitro
|
|
|
|
EU Competent Authorities for Dangerous Substances Directive
|
| |
Isolated chicken eye (ICE) test |
In vitro or Ex vivo
|
ICCVAM (2007)
|
ESAC 28 (2007)
INVITTOX Protocol 80
JaCVAM (2009)
JaCVAM Regulatory Acceptance Board (2009)
|
OECD TG 438 (2009)
OECD Proficiency Standards
Draft OECD GD on Supplement to TG 437 and 438 (histopathology) (2009)
|
|
| |
Isolated rabbit eye test |
In vitro or Ex vivo
|
|
|
|
EU Competent Authorities for Dangerous Substances Directive
|
| |
Routine use of topical anesthetics, systemic analgesics, and humane endpoints |
In vivo
|
ICCVAM (2009)
|
|
Expected 2012
|
|
| Eye irritation |
Cytosensor Microphysiometer modified (cytotoxicity/cell-function based in vitro assay) |
In vitro
|
ESAC 40 (2009)4
INVITTOX Protocol 102 modified
|
ICCVAM (2010)5
|
Draft OECD TG (2010)
|
|
| |
Rabbit low-volume eye test (LVET) |
In vivo
|
ESAC 41 (2009)7
|
ICCVAM (2009)8
|
|
|
| |
Routine use of topical anesthetics, systemic analgesics, and humane endpoints |
In vivo
|
ICCVAM (2009)
|
|
Expected 2012
|
|
| Genotoxicity |
Bacterial reverse mutation (Ames) test |
In vitro
|
|
|
OECD TG 471 (1997)
|
|
| |
In vitro cell gene mutation test |
In vitro
|
|
|
OECD TG 476 (1997)
|
|
| |
In vitro chromosomal aberration test |
In vitro
|
|
|
OECD TG 473 (1997)
|
|
| |
In vitro mammalian cell micronucleus test |
In vitro
|
ESAC 24 (2006)
|
ICCVAM comments to OECD
|
OECD TG 487 (2010)
|
|
| |
In vitro sister chromatid exchange test |
In vitro
|
|
|
OECD TG 479 (1986)
|
|
| |
In vitro unscheduled DNA synthesis test |
In vitro
|
|
|
OECD TG 482 (1986)
|
|
| |
Saccharomyces cerevisiae gene mutation assay |
In vitro
|
|
|
OECD TG 480 (1986)
|
|
| |
Saacharomyces cerevisiae mitotic recombination assay |
In vitro
|
|
|
OECD TG 481 (1986)
|
|
| Hematotoxicity: acute neutropenia |
Colony forming unit granulocyte macrophage (CFU-GM) assay |
In vitro
|
ESAC 18 (2006)
|
|
|
Submitted to EMEA
|
| Immunotoxicity/Skin Sensitization |
Local lymph node assay (LLNA) |
In vivo
|
ICCVAM (1999)
ICCVAM Protocol and Performance Standards (2009)
|
ESAC 6 (2000)
|
OECD TG 429 (2002)
Updated OECD TG 429 (2010)
|
|
| |
Reduced LLNA: rLLNA9 |
In vivo
|
ESAC 29 (2007)
Performance Standards: ESAC 37 (2008)
|
ICCVAM (2009)
Performance Standards (2009)
|
Updated OECD TG 429 (2010)
|
|
| |
Nonradiolabelled LLNA: DA |
In vivo
|
JaCVAM (2008)
JaCVAM Regulatory Acceptance Board (2008)
|
ICCVAM (2009)10
|
OECD TG 442A (2010)
|
|
| |
Nonradiolabelled LLNA: BrdU-ELISA |
In vivo
|
ICCVAM (2009)10
|
JaCVAM (2010)
JaCVAM Regulatory Acceptance Board (2010)
|
OECD TG 442B (2010)
|
|
| |
LLNA for Potency Categorization |
In vivo
|
ICCVAM (2009)
|
|
UN GHS (2009)
|
US agencies (anticipated 2011)
|
| Phototoxicity |
3T3 Neutral Red Uptake Phototoxicity Test |
In vitro
|
ESAC 1 (1997)
|
|
OECD TG 432 (2004)
|
|
| |
3T3 NRU Phototoxicity Test: Application to UV filter chemicals |
In vitro
|
ESAC 4 (1998)
|
|
OECD TG 432 (2004)
|
|
| Pyrogenicity |
Human whole blood IL-1 |
In vitro
|
ESAC 19 (2006)
|
ICCVAM (2008)11
|
|
EMEA; European Pharmacopeia; US agencies
|
| |
Human whole blood IL-6 |
In vitro
|
ESAC 20 (2006)
|
ICCVAM (2008)11
|
|
EMEA; European Pharmacopeia; US agencies
|
| |
Human cryopreserved whole blood IL-1 |
In vitro
|
ESAC 23 (2006)
|
ICCVAM (2008)11
|
|
EMEA; European Pharmacopeia; US agencies
|
| |
PBMC IL-6 |
In vitro
|
ESAC 21 (2006)
|
ICCVAM (2008)11
|
|
EMEA; European Pharmacopeia; US agencies
|
| |
MM6 IL-6 |
In vitro
|
ESAC 22 (2006)
|
ICCVAM (2008)11
|
|
EMEA; European Pharmacopeia; US agencies
|
| |
Limulus amebocyte lysate (LAL) test |
In vitro
|
|
|
|
European Pharmacopeia (5.0); US Pharmacopeia (85)
|
| Reproductive & developmental toxicity |
Embryonic stem cell test for embryotoxicity |
In vitro
|
ESAC 13 (2002)
|
|
See Draft OECD GD 43, page 18
|
|
| |
Micromass embryotoxicity assay |
Ex vivo
|
ESAC 11 (2002)
|
|
|
|
| |
Whole rat embryotoxicity assay |
Ex vivo
|
ESAC 12 (2002)
|
|
|
|
| |
Extended one-generation reproductive toxicity study |
In vivo
|
|
|
OECD TG 443 (2011)
|
|
| Skin corrosion |
EST-1000 human reconstructed epidermis |
In vitro
|
ESAC 39 (2009)
ESAC 43 (2009)12
|
|
OECD TG 431 (2004)
Draft Updated TG 431 (2009)
|
|
| |
Corrositex® noncellular membrane |
In vitro
|
ICCVAM (1999)
|
ESAC 8 (2000)
|
OECD TG 435 (2006)
|
|
| |
EpiSkin® human skin model |
In vitro
|
ESAC 2 (1998)
ESAC 43 (2009)12
|
ICCVAM (2002)
Performance Standards (2004)
|
OECD TG 431 (2004)
Draft Updated TG 431 (2009)
|
|
| |
EpiDermTM human skin model |
In vitro
|
ESAC 7 (2000)
ESAC 43 (2009)12
|
ICCVAM (2002)
Performance Standards (2004)
|
OECD TG 431 (2004)
Draft Updated TG 431 (2009)
|
|
| |
Rat skin transcutaneous electrical resistance (TER)assay |
Ex vivo
|
ESAC 3 (1998)
|
ICCVAM (2002)
Performance Standards (2004)
|
OECD TG 430 (2004)
Draft Updated TG 430 (2009)
|
|
| |
SkinEthicTM human skin model |
In vitro
|
ESAC 25 (2006)
ESAC 43 (2009)12
|
ICCVAM
|
OECD TG 431 (2004)
Draft Updated TG 431 (2009)
|
|
| |
Vitrolife-Skin human reconstructed epidermis |
In vitro
|
JaCVAM (2008)
JaCVAM Regulatory Acceptance Board (2008)
|
ESAC 43 (2009)12
|
OECD TG 431 (2004)
Draft Updated TG 431 (2009)
|
|
| Skin irritation |
EpiSkin® skin irritation test (with MTT reduction) |
In vitro
|
ESAC 31 (2007)
ESAC 38 (2009) (Performance under UN GHS; Reference Chemicals; Performance Standards)
ESAC 42 (2009) (Updated Performance Standards)
|
JaCVAM (2010)
JaCVAM Regulatory Acceptance Board (2010)
|
OECD TG 439 (2010)
|
|
| |
EpiDermTM skin irritation test (with MTT reduction) |
In vitro
|
ESAC 30 (2007)13
|
|
|
EU test method B.46 in COM regulation 440/2008/EC
|
| |
EpiDermTM SIT model (EPI-200) |
In vitro
|
ESAC 36 (2008)
ESAC 38 (2009) (Performance under UN GHS; Reference Chemicals; Performance Standards)
ESAC 42 (2009) (Updated Performance Standards)
|
|
OECD TG 439 (2010)
|
|
| |
SkinEthic RHE model |
In vitro
|
ESAC 36 (2008)
ESAC 38 (2009) (Performance under UN GHS; Reference Chemicals; Performance Standards)
ESAC 42 (2009) (Updated Performance Standards)
|
|
OECD TG 439 (2010)
|
|